IAA
ARQT icon

Independent Advisor Alliance’s Arcutis Biotherapeutics ARQT Stock Holding History

Independent Advisor Alliance’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$667K Sell
25,436
-6,161
-19% -$144K 0.02% 579
2026
Q1 		$744K Buy
31,597
+6,294
+25% +$161K 0.01% 965
2025
Q4 		$735K Buy
25,303
+5,069
+25% +$130K 0.02% 549
2025
Q3 		$381K Buy
20,234
+8,922
+79% +$141K 0.01% 703
2025
Q2 		$159K Buy
+11,312
New +$159K ﹤0.01% 853

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Independent Advisor Alliance's ARQT Position: Q2 2026 in Review

Independent Advisor Alliance reduced its Arcutis Biotherapeutics (ARQT) stake by 19% in Q2 2026, selling an estimated $144K and leaving 25,436 shares worth $667K. The position accounts for 0.02% of the portfolio, ranked #579.

Independent Advisor Alliance first reported a position in ARQT in Q2 2025 and has held it in 5 quarters since. The position peaked at $744K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Independent Advisor Alliance held 25,436 shares of Arcutis Biotherapeutics worth $667K as of Q2 2026.
  • Independent Advisor Alliance sold 6,161 Arcutis Biotherapeutics shares in Q2 2026, an estimated $144K.
  • Arcutis Biotherapeutics made up 0.02% of Independent Advisor Alliance's portfolio in Q2 2026, its #579 holding.
  • Independent Advisor Alliance first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • Independent Advisor Alliance's Arcutis Biotherapeutics position peaked at $744K in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Independent Advisor Alliance's 13F filing for Q2 2026, filed 12 Aug 2026.